Cambridge, MA, United States of America

Jeremy Lee Baryza

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 9.9

ph-index = 5

Forward Citations = 41(Granted Patents)


Location History:

  • Quincy, MA (US) (2016 - 2021)
  • Cambridge, MA (US) (2016 - 2021)

Company Filing History:


Years Active: 2016-2021

where 'Filed Patents' based on already Granted Patents

11 patents (USPTO):

Title: Jeremy Lee Baryza: Innovator in RNA Therapeutics

Introduction

Jeremy Lee Baryza is an accomplished inventor based in Cambridge, MA, USA, known for his significant contributions to the field of RNA therapeutics. With 11 patents to his name, he has made strides in developing innovative solutions for treating various metabolic diseases.

Latest Patents

Among his latest patents are "Organic compositions to treat APOC3-related diseases," which outlines methods and compositions for addressing disorders such as hypertriglyceridemia and Type 2 diabetes through the use of RNA interference (RNAi) agents targeting APOC3. Additionally, he has patented "3' end caps for RNAi agents for use in RNA interference," which details novel compounds that enhance the effectiveness of RNAi agents. His work focuses on improving treatment methodologies for conditions linked to abnormal metabolism and cholesterol metabolism.

Career Highlights

Jeremy has had a fruitful career working with prominent companies in the pharmaceutical and biotechnology sectors. Notably, he has held positions at Novartis AG and Arrowhead Pharmaceuticals, Inc., where he has leveraged his expertise to advance pharmaceutical research and innovation.

Collaborations

Throughout his career, Jeremy has collaborated with other skilled professionals in his field, including Junping Zhao and Jan Weiler. These partnerships have allowed him to enhance the development of therapeutic approaches and foster innovative ideas in RNA therapeutics.

Conclusion

In summary, Jeremy Lee Baryza stands out as a notable inventor whose work has the potential to transform the treatment landscape for various metabolic diseases. With his ongoing contributions and collaborations, he continues to push the boundaries of innovation in biopharmaceuticals and RNA technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…